• Gallein: G Protein βγ Subunit Inhibitor Guide

  2026-08-28

  Gallein is a G protein βγ subunit inhibitor for experimentally dissecting GPCR signaling pathway outputs. Product and model data support applications in cancer metastasis inhibition, macrophage polarization modulation, and an autoimmune myocarditis treatment model, while a 2026 Cell Research study provides a related but distinct GPR81 metabolic signaling context.

• ABT-263 Workflow for Apoptosis Research

  2026-08-28

  Build sharper apoptosis assays with ABT-263 (Navitoclax), from DMSO stock preparation and dose–response design to caspase and viability readouts. The workflow also shows how the compound can expose the limits of apoptosis-resistant CHO 4BGD cells in cancer biology and bioprocess stress testing.

• KAS-ATAC Sequencing for Accessible ssDNA Genomes

  2026-08-27

  The KAS-ATAC protocol combines N3-kethoxal labeling of single-stranded DNA with Tn5-based chromatin accessibility profiling to identify genomic regions that are both physically accessible and contain ssDNA structures. The workflow provides a practical route for integrating transcription-associated DNA structures with regulatory chromatin maps, while its interpretation requires careful attention to labeling chemistry, native chromatin handling, enrichment, and sequencing biases.

• EdU Imaging Kits (488): 5 Lab Scenarios

  2026-08-26

  This scenario-based guide explains how EdU Imaging Kits (488), SKU K1175, can improve S-phase DNA synthesis measurement when metabolic assays, BrdU workflows, or inconsistent sample handling create ambiguity. It covers assay design, click-chemistry workflow, interpretation, and practical vendor-selection criteria for microscopy and flow cytometry.

• From ISG20 Signal to Atherosclerosis Mechanism

  2026-08-26

  A translational framework for converting ISG20 and CLEC5A observations into spatially resolved, experimentally defensible atherosclerosis evidence. The article explains how HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody can strengthen fluorescence workflows across macrophage, endothelial, and plaque studies while addressing multiplexing, controls, and assay reproducibility.

• RG108: A Practical Guide to DNMT Assay Design

  2026-08-26

  RG108 is a DNA methyltransferase inhibitor suited to mechanistic epigenetics and cancer research. This guide focuses on interpreting biochemical versus cellular data, selecting orthogonal endpoints, and applying lessons from a recent antiviral mechanism study without overstating what RG108 can prove.

• Difloxacin HCl: Assay Workflows for Resistance Research

  2026-08-25

  Difloxacin HCl supports two distinct research paths: organism-level antimicrobial susceptibility testing and exploratory multidrug resistance reversal in neuroblastoma models. This guide connects formulation, assay controls, and troubleshooting with a checkpoint-regulation study without overstating evidence across biological systems.

• CX-5461: Mapping Pol I Stress to Tumor Cell Fate

  2026-08-24

  CX-5461 is an RNA polymerase I inhibitor that connects ribosome biogenesis disruption with DNA damage, mitotic failure, autophagy, and senescence. This guide provides an assay-centered framework for interpreting tumor-cell responses and designing more informative cancer research workflows.

• LRPPRC–Dasatinib Synergy in OXPHOS Cancer

  2026-08-24

  The reference study identifies dasatinib as a synergistic partner for LRPPRC inhibition, revealing complementary suppression of nuclear- and mitochondrial genome-encoded oxidative phosphorylation programs. Its screening and mechanistic design provide a rationale for dual-genome OXPHOS disruption while also highlighting the need for biomarker-guided validation beyond cell models.

• Tofacitinib Citrate: From JAK3 to Vascular Insight

  2026-08-23

  A translational perspective on Tofacitinib citrate and CP-690550 citrate, connecting JAK3-preferring immune modulation with concentration-aware endothelial experiments, comparative JAK inhibitor biology, and practical study design.

• Vernakalant for Rapid Atrial Fibrillation Conversion

  2026-08-22

  This phase 3 randomized trial showed that intravenous vernakalant rapidly converted recent-onset atrial fibrillation to sinus rhythm, with a substantially higher response than placebo and a median conversion time of 11 minutes. Its main contribution was clinical validation of an atrium-oriented electrophysiological strategy, while the safety findings underscore the need for careful patient selection and monitoring.

• HYPK, NatA, and Ribosome Exchange in Protein Acetylation

  2026-08-21

  The reference study shows that HYPK promotes global N-terminal acetylation not by simply increasing NatA catalysis, but by accelerating NatA exchange between ribosomes. This kinetic mechanism explains how sub-stoichiometric NatA can modify a broad nascent proteome and establishes ribosome residence time as a central variable in cotranslational protein maturation.

• Rotigotine’s Antidepressant Activity in Rat Models

  2026-08-20

  The reference study examined rotigotine across several rat models of anxiety and depression, showing antidepressant-like effects at lower doses while identifying locomotor stimulation as an important high-dose confound. Its multi-model design provides a useful framework for interpreting dopamine-dependent behavioral effects in Parkinson’s disease research.

• Self-Amplifying RNA for Influenza Dose Sparing

  2026-08-20

  This 2026 study shows that RNA vaccine performance depends strongly on both influenza subtype and platform design. Self-amplifying RNA produced durable antibody responses and complete homologous influenza B protection at a low dose in mice, overcoming a weakness observed with conventional nucleoside-modified mRNA.

• GI 254023X: Precision in ADAM10 Translation

  2026-08-19

  GI 254023X illustrates how selective ADAM10 inhibition can connect sheddase biology with actionable translational experiments in signaling and vascular injury. This thought-leadership perspective outlines a mechanism-first workflow, interprets cross-domain lessons from partial BACE inhibition, and defines the evidence needed to move ADAM10 research beyond product-page pharmacology.

8440 records 1/563 page Next 12345 下5页 Last page